€109.60-2.30 (-2.06%)
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific.
Merck KGaA in the Healthcare sector is trading at €109.60. The stock is currently 17% below its 52-week high of €131.65, remaining 3.1% below its 200-day moving average. Technical signals show neutral RSI of 59 and bullish MACD crossover, explaining why MRK.DE maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs...
Sales rose 14% to €10.51 billion at constant currency, boosted by new launches and recent acquisitions.
It looks like Merck KGaA ( ETR:MRK ) is about to go ex-dividend in the next three days. The ex-dividend date is...
Recent performance and business mix Merck KGaA (XTRA:MRK) has drawn investor attention after a mixed share performance, with an 8.3% gain over the past month set against a 9.1% decline over the past 3 months. The company operates across three main segments: Healthcare, Life Science, and Electronics. Healthcare and Life Science generate most of its €21,102m revenue, with Electronics contributing a smaller but meaningful share. Recent annual figures show revenue of €21,102m and net income of...
The acquisition will add Belgium-based chromatography operations and a team of over 50 employees to Merck.
Sanofi (NASDAQ:SNY) is included among the 15 Large Cap Stocks with Highest Dividends. Sanofi (NASDAQ:SNY) is a healthcare biopharmaceutical company that engages in the research, development, manufacture, and marketing of therapeutic solutions. On March 19, Bernstein analyst Justin Smith initiated coverage of Sanofi (NASDAQ:SNY) with an ‘Outperform’ rating and a price target of €110. The […]